Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Sep-24 7:00 PM View:  | Saad Mark E Director | Axsome Therapeutics, Inc. (AXSM) | 11-Sep-24 | Option Exercise | 11,016 | $3.67 | $40,428.70 | 107% 10.3K to 21.32K | |
| 11-Sep-24 7:00 PM View: | Saad Mark E Director | Axsome Therapeutics, Inc. (AXSM) | 11-Sep-24 | Planned Option Sale | 11,016 | $91.31 | $1,005,870.00 | (52%) 21.32K to 10.3K | |
| 09-Aug-24 7:27 PM View: | Jacobson Mark L. Chief Operating Officer | Axsome Therapeutics, Inc. (AXSM) | 09-Aug-24 | Planned Option Sale | 47,739 | $84.26 | $4,022,490.00 | (89%) 53.52K to 5.78K | |
| 09-Aug-24 7:27 PM View: | Jacobson Mark L. Chief Operating Officer | Axsome Therapeutics, Inc. (AXSM) | 09-Aug-24 | Option Exercise | 47,739 | $4.04 | $192,866.00 | 826% 5.78K to 53.52K | |
| 29-May-24 8:12 PM View: | Jacobson Mark L. Chief Operating Officer | Axsome Therapeutics, Inc. (AXSM) | 29-May-24 | Option Sale | 7,910 | $74.31 | $587,813.00 | (58%) 13.69K to 5.78K | |
| 29-May-24 8:12 PM View: | Jacobson Mark L. Chief Operating Officer | Axsome Therapeutics, Inc. (AXSM) | 29-May-24 | Option Exercise | 13,693 | $1.30 | $17,800.90 | 100% 0 to 13.69K | |
| 29-May-24 8:11 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 29-May-24 | Sale (Planned) | 5,248 | $75.14 | $394,333.00 | (26%) 19.85K to 14.6K | |
| 29-May-24 8:11 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 28-May-24 | Private Sale (Planned) | 5,249 | $75.21 | $394,775.00 | (21%) 25.1K to 19.85K | |
| 01-Apr-24 6:46 PM View: | Jacobson Mark L. Chief Operating Officer | Axsome Therapeutics, Inc. (AXSM) | 01-Apr-24 | Planned Option Sale | 24,662 | $77.24 | $1,904,940.00 | (100%) 24.66K to 0 | |
| 01-Apr-24 6:46 PM View: | Jacobson Mark L. Chief Operating Officer | Axsome Therapeutics, Inc. (AXSM) | 01-Apr-24 | Option Exercise | 24,662 | $1.30 | $32,060.60 | 100% 0 to 24.66K | |
| 15-Mar-24 8:05 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 15-Mar-24 | Planned Option Sale | 2,347 | $71.61 | $168,062.00 | (1%) 170.01K to 167.67K | |
| 15-Mar-24 8:05 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 15-Mar-24 | Option Exercise | 2,347 | $29.91 | $70,198.80 | 1% 167.67K to 170.01K | |
| 15-Mar-24 8:05 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 14-Mar-24 | Planned Option Sale | 29,976 | $69.70 | $2,089,390.00 | (15%) 197.64K to 167.67K | |
| 15-Mar-24 8:05 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 14-Mar-24 | Option Exercise | 29,976 | $24.01 | $719,787.00 | 18% 167.67K to 197.64K | |
| 15-Sep-23 6:30 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 15-Sep-23 | Option Exercise | 11,016 | $3.67 | $40,428.70 | 2% 447.52K to 458.54K | |
| 15-Sep-23 6:30 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 15-Sep-23 | Planned Option Sale | 11,016 | $75.19 | $828,241.00 | (2%) 458.54K to 447.52K | |
| 15-Sep-23 6:30 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 15-Sep-23 | Sale (Planned) | 18,572 | $75.18 | $1,396,190.00 | (4%) 447.52K to 428.95K | |
| 04-Jan-23 4:11 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 03-Jan-23 | Option Exercise | 17,501 | $1.30 | $22,751.30 | 4% 430.02K to 447.52K | |
| 17-Mar-22 7:05 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 15-Mar-22 | Option Exercise | 3,496 | $1.30 | $4,544.80 | < 1% 426.53K to 430.02K | |
| 23-Nov-21 7:30 AM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 19-Nov-21 | Market Purchase | 3,950 | $37.30 | $147,350.00 | 2% 163.72K to 167.67K | (1%) |
| 22-Nov-21 7:31 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 18-Nov-21 | Market Purchase | 527 | $35.50 | $18,708.50 | 1% 41.32K to 41.85K | < 1% |
| 22-Nov-21 7:30 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 18-Nov-21 | Market Purchase | 1,430 | $35.09 | $50,180.70 | < 1% 425.1K to 426.53K | 2% |
| 22-Nov-21 7:31 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 18-Nov-21 | Market Purchase | 428 | $34.97 | $14,967.50 | 1% 41.85K to 42.28K | 2% |
| 19-Nov-21 7:30 AM View: | Saad Mark E Director | Axsome Therapeutics, Inc. (AXSM) | 17-Nov-21 | Market Purchase | 3,000 | $34.53 | $103,597.00 | 44% 6.8K to 9.8K | 3% |
| 19-Nov-21 7:30 AM View: | Saad Mark E Director | Axsome Therapeutics, Inc. (AXSM) | 17-Nov-21 | Market Purchase | 300 | $34.42 | $10,324.50 | 3% 9.8K to 10.1K | 3% |
| 13-May-21 7:05 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 12-May-21 | Market Purchase | 500 | $58.15 | $29,075.00 | < 1% 424.6K to 425.1K | (2%) |
| 20-Aug-20 8:43 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 19-Aug-20 | Gift | 397,998 | -- | -- | 97% 408.8K to 806.8K | |
| 20-Aug-20 8:43 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 19-Aug-20 | Gift | 397,998 | -- | -- | (49%) 806.8K to 408.8K | |
| 30-Jun-20 8:20 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 29-Jun-20 | Market Purchase | 650 | $78.50 | $51,025.00 | < 1% 408.15K to 408.8K | |
| 30-Jun-20 8:19 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 29-Jun-20 | Market Purchase | 777 | $76.64 | $59,549.30 | 2% 40.5K to 41.28K | |
| 14-Jan-20 4:08 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 10-Jan-20 | Option Exercise | 60,186 | $10.46 | $629,756.00 | 58% 103.53K to 163.72K | |
| 30-Sep-19 7:16 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 26-Sep-19 | Market Purchase | 2,180 | $24.80 | $54,064.00 | 6% 38.32K to 40.5K | (7%) |
| 05-Jul-19 7:00 AM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 03-Jul-19 | Option Exercise | 56,620 | $3.04 | $172,178.00 | 121% 46.91K to 103.53K | |
| 27-Jun-19 7:18 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 26-Jun-19 | Market Purchase | 15,800 | $23.10 | $364,980.00 | 2% 658.15K to 673.95K | (< 1%) |
| 27-Jun-19 7:18 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 25-Jun-19 | Market Purchase | 400 | $23.25 | $9,300.00 | < 1% 657.75K to 658.15K | (1%) |
| 12-Jun-19 7:00 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 11-Jun-19 | Market Purchase | 1,920 | $20.80 | $39,936.00 | 100% 0 to 1.92K | < 1% |
| 24-May-19 7:19 AM View: | Saad Mark E Director | Axsome Therapeutics, Inc. (AXSM) | 23-May-19 | Market Purchase | 3,500 | $22.33 | $78,155.00 | 100% 3.5K to 7.0K | 6% |
| 15-May-19 7:21 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 13-May-19 | Market Purchase | 4,650 | $21.44 | $99,696.00 | < 1% 653.1K to 657.75K | 1% |
| 21-Mar-19 7:05 AM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 19-Mar-19 | Market Purchase | 5,100 | $12.18 | $62,118.00 | < 1% 648.0K to 653.1K | (1%) |
| 21-Mar-19 7:05 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 19-Mar-19 | Market Purchase | 60 | $12.69 | $761.40 | < 1% 31.0K to 31.06K | (5%) |
| 21-Mar-19 7:05 AM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 19-Mar-19 | Market Purchase | 5,340 | $12.58 | $67,177.20 | 17% 31.06K to 36.4K | (5%) |
| 20-Jun-18 5:00 PM View: | Pizzie Nick Chief Financial Officer | Axsome Therapeutics, Inc. (AXSM) | 19-Jun-18 | Market Purchase | 31,000 | $3.10 | $96,080.00 | 100% 0 to 31.0K | 206% |
| 30-Mar-17 4:31 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 29-Mar-17 | Option Exercise | 42,538 | $4.73 | $201,163.00 | 973% 4.37K to 46.91K | |
| 24-Dec-15 1:02 PM View: | Kaye Randall Chief Medical Officer | Axsome Therapeutics, Inc. (AXSM) | 23-Dec-15 | Market Purchase | 1,000 | $9.03 | $9,026.00 | 20% 5.02K to 6.02K | 7% |
| 24-Nov-15 4:26 PM View: | Ames Constance Vice President, Finance | Axsome Therapeutics, Inc. (AXSM) | 24-Nov-15 | Conversion | 4,358 | $5.94 | $25,886.50 | 100% 0 to 4.36K | |
| 24-Nov-15 4:24 PM View: | Tabuteau Herriot Chief Executive Officer Director 10% Owner | Axsome Therapeutics, Inc. (AXSM) | 24-Nov-15 | Conversion | 7,229 | $5.94 | $42,940.30 | < 1% 7.34M to 7.35M | |
| 24-Nov-15 4:26 PM View: | Kaye Randall Chief Medical Officer | Axsome Therapeutics, Inc. (AXSM) | 24-Nov-15 | Conversion | 5,022 | $5.40 | $27,118.80 | 100% 0 to 5.02K | |
| 24-Nov-15 4:25 PM View: | Jeffs Roger Director | Axsome Therapeutics, Inc. (AXSM) | 24-Nov-15 | Conversion | 4,374 | $5.94 | $25,981.60 | 100% 0 to 4.37K | |
| 24-Nov-15 4:24 PM View: | Saad Mark E Director | Axsome Therapeutics, Inc. (AXSM) | 24-Nov-15 | Conversion | 3,502 | $5.94 | $20,801.90 | 100% 0 to 3.5K | |
| 24-Nov-15 4:25 PM View: | Coleman Mark Director | Axsome Therapeutics, Inc. (AXSM) | 24-Nov-15 | Conversion | 564,948 | $5.71 | $3,224,170.00 | 680% 83.05K to 648.0K |
